Rationale: Assessment of the inflammatory response can help the decision-making process when diagnosing community-acquired pneumonia (CAP), but there is a lack of information about the influence of time since onset of symptoms.
Community-acquired pneumonia (CAP) remains an important infectious disease, with a significant global burden, and is considered a major cause of sepsis worldwide (1, 2) . Appropriate initial severity assessment and management at the emergency room (ER) can improve the prognosis, result in fewer complications, and reduce costs (3, 4) .
In recent decades, physicians have made initial assessments of pneumonia on the basis of symptoms, physical examination, and complementary data (e.g., X-rays or laboratory tests) supported by prognostic scales like the Pneumonia Severity Index (PSI), CURB65 (confusion, urea, respiratory rate, blood pressure, 65 years) (5, 6) , or the more recent quick Sequential Organ Failure Assessment (7) . Over time, these scales have been combined with biomarkers and inflammatory cytokines to improve the decision-making process and to predict poor outcomes (8, 9) . In the diagnostic process of lower respiratory tract infections and in sepsis, procalcitonin (PCT) levels have been used to decide both antibiotic initiation and its duration (10) (11) (12) (13) . Moreover, treatment may differ based on initial inflammatory biomarker levels, as corticosteroid treatment was found to reduce treatment failure in patients with high initial CRP levels (14) .
The interest in knowing the different patterns of inflammation and their related factors has led to a better understanding of the immunopathogenic process that occurs in CAP (15) (16) (17) . The natural course of the infection and its systemic inflammatory pattern before diagnosis is rather unknown, although presumably it can differ depending on the duration of the infection and the distinct kinetics of inflammatory cytokines and biomarkers. Our hypothesis was that time since onset of symptoms influences the systemic concentrations of inflammatory cytokine and biomarker levels at CAP diagnosis, mainly during the first hours, when bacterial growth is taking place and the host is mounting the inflammatory response. So far, there is a lack of published data about this aspect, which we considered key for interpreting the initial inflammatory pattern in CAP.
Accordingly, we aimed to evaluate the influence of time since onset of symptoms on the initial levels of inflammatory cytokines and biomarkers at CAP diagnosis in hospitalized patients. In addition, our findings were evaluated in a different cohort with data of biomarkers at CAP diagnosis. Some of the results of these studies have been previously reported in the form of an abstract (18, 19) .
Methods

Design and Study Population
The study involved secondary analyses of data from two prospective longitudinal cohorts. (20) .
CAP was diagnosed if new acute respiratory symptoms, signs, and compatible infiltrate(s) on chest X-ray were present. Exclusion criteria were younger than 18 years of age, other active infection, admission within the prior 15 days, nursing home residence, and immunocompromised (e.g., transplant recipients, patients with malignancies, HIV-positive patients, or treatment with >20 mg/d of prednisone or equivalent for .14 d). We also excluded patients with chronic liver disease, because C-reactive protein (CRP) is mainly produced in hepatocytes after stimulation by some ILs (21, 22) .
Data Collection and Definitions
We collected data on demographic characteristics and comorbidities (i.e., diabetes mellitus and respiratory, heart, liver, neurological, and renal diseases). The severity of disease at presentation was assessed with the PSI, and sepsis was defined according to the updated clinical criteria reported by the Sepsis-3 Task Force (5, 23) . Antibiotic treatment before CAP diagnosis in the current episode was recorded.
The time, measured in days since the onset of CAP symptoms and/or signs until diagnosis at the ER, was self-reported by patients themselves or by close relatives during clinical interview. Any respiratory symptoms and/or signs (i.e., chest pain, cough, expectoration, dyspnea, chills, and temperature > 37.8 8 C) related to the acute process were considered. According to symptom onset, patients were divided into two groups: "early presenters" if time was less than 3 days and "nonearly presenters" if greater than or equal to 3 days. That threshold was selected taking into account the fact that during the first 48 hours, bacterial growth is increasing and systemic inflammation is escalating, as observed in animal models of pneumonia (24) (25) (26) .
At a Glance Commentary
Scientific Knowledge on the Subject: A correct interpretation of the inflammatory response at diagnosis of community-acquired pneumonia (CAP) can improve initial assessment of severity, management, and prediction of outcome. So far, evaluation of initial inflammatory cytokines and biomarkers is performed without considering time since onset of symptoms, which could modify systemic biomarker levels depending on its own kinetics and the phase of infection.
What This Study Adds to the
Field: This study demonstrates that time elapsed from symptom onset to CAP diagnosis influences the systemic inflammatory profile differently for each cytokine. Patients with 3 or more days since symptom onset showed lower levels of procalcitonin, IL-6, and IL-8, whereas those with less than 3 days had lower levels of C-reactive protein, even in those with sepsis. These findings provide new insight about the most useful window period for biomarker analyses: procalcitonin within the first 48 hours since onset of symptoms and C-reactive protein, IL-6, and IL-8 for those with 3 or more days. Onset of CAP symptoms should be considered at diagnosis to avoid underestimating the inflammatory response and for the future design of randomized clinical trials.
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Outcomes evaluated were length of stay and mortality during hospitalization and at 30 days after hospital admission.
Microbiological Tests
The following microbiological studies were performed: paired blood cultures, urinary antigens for Legionella pneumophila and Streptococcus pneumoniae, sputum Gram stain (if ,10 epithelial cells and .25 leukocytes per field; magnification 3100) and culture, and paired serological studies for Chlamydophila pneumoniae, Mycoplasma pneumoniae, Coxiella burnetii, and Legionella pneumophila. Invasive samples by bronchoscopy and/or pleurocentesis were obtained if required by the attending physician.
Study of Biomarkers and Cytokines
Venous blood samples were obtained within the first 24 hours of hospital admission and processed to acquire serum, which was stored at 280 8 C until analysis. Determination of cytokines was made using an enzyme immunoassay (BioSource) according to the manufacturer's instructions. Cytokines were only analyzed in the derivation cohort. The cytokines of interest were IL-1, IL-6, IL-8, IL-10, and tumor necrosis factor (TNF)-a. PCT levels were determined using an immunoluminometric technique (Liason Brahms PCT) with a detection limit of 0.03 ng/ml. CRP was detected using an immunoturbidimetric test (Bayer Diagnostics) with a detection limit of 0.15 mg/L. In the validation cohort, PCT levels were determined using an electrochemiluminescence immunoassay in a Cobas 6000e autoanalyzer (Roche Diagnostics), with an analytical sensitivity of 0.02 ng/ml and coefficients of variation, obtained in routine (one run daily), of 3.26% (0.51 ng/ml) and 4.72% (9.48 ng/ml). CRP levels were measured using an immunoturbidimetric method in a Cobas 6000c autoanalyzer (Roche Diagnostics) with an analytical sensitivity of 1 mg/L and coefficients of variation obtained in routine (one run daily) of 4.85% (9.33 mg/L) and 5.61% (40.63 mg/L).
Statistical Analysis
Statistical analyses were performed using IBM SPSS 20.0 software (SPSS). Patients were grouped and compared with regard to classification as early or nonearly presenters. Baseline characteristics, comorbidity, previous antibiotic treatment, prognostic scales, severity (i.e., PSI), and the presence of sepsis were analyzed and compared. Categorical variables were presented as n (%) and compared with the x 2 test, and continuous variables were presented as medians and interquartile ranges (IQRs) and analyzed with the Mann-Whitney U test. Values of P , 0.05 were considered significant. Radar plots were built to illustrate the concentration of cytokines and biomarkers according to time since onset of symptoms.
Results
Patient Baseline Characteristics
We included 584 patients in the derivation cohort and 422 in the validation cohort ( Figure 1 ). The median duration since onset of symptoms until CAP diagnosis in the ER was 5 days in both cohorts (IQR, 3-7 d). A total of 122 patients (22.6%) in the derivation cohort and 82 (20.6%) in the validation cohort had attended the ER within the first 48 hours of symptoms (early presenters). Early presenters were older, had more comorbidities, and had greater initial CAP severity in both cohorts. By contrast, nonearly presenters had more often received antibiotic treatment before admission. The most notable differences between the two cohorts were pneumococcal vaccination, previous antibiotic treatment, and change in mental status (less frequent in the validation cohort). Longer length of stay was found in early presenters in the derivation cohort but not in the validation cohort. No significant differences in other outcomes were found when comparing the two cohorts (Table 1) . previous antibiotic treatment. No significant differences were found for any of the biomarkers or cytokines with regard to previous antibiotic treatment (see Table E1 in the online supplement). CRP levels were highest in patients with 3 or more days of symptoms, whereas PCT, IL-6, and IL-8 showed higher levels in patients with less than 3 days of symptoms (Table 2) . Early presenters had significantly lower CRP concentrations and higher PCT, IL-6, and IL-8 concentrations. Figure 3 shows all biomarkers and cytokines expressed in deciles of concentrations in the derivation cohort in early and nonearly presenters.
Validation cohort. Early presenters also showed significantly lower levels of CRP in comparison to nonearly presenters ( Table 2 ). The median levels of CRP were 38.2% greater in patients with 3 or more days since onset of symptoms than in those with less than 3 days, and 36.4% in the derivation cohort. By contrast, higher levels of PCT were found in those patients with early presentation. The median levels of PCT were 40% lower in patients with 3 or more days since onset of symptoms in comparison with those with less than 3 days in the derivation cohort and 56% in the validation cohort.
Biomarkers and Cytokines by Initial Severity: PSI and Sepsis
Derivation cohort. When we analyzed data according to severity, in patients with mild disease (PSI I-III), PCT and IL-6 levels were lower in those with longer duration of Data are presented as n (%) or median (interquartile range).
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symptoms; by comparison, patients with more severe disease (PSI IV-V) and less than 3 days of symptoms had lower CRP levels (Table 3) . Patients with sepsis showed significantly higher levels of CRP than those without sepsis. There were lower levels of CRP in patients with less than 3 days since onset of symptoms when compared with those with 3 or more days, irrespective of the presence of sepsis ( Figure 4A ). PCT levels in early presenters with sepsis were higher than in those without sepsis in the derivation cohort (P , 0.05) ( Figure 4B ). Validation cohort. In patients with mild disease (PSI I-III), significantly lower levels of CRP were found in early presenters, with a trend, which did not reach statistical significance, in those with PSI IV or V. No significant differences were found in PCT (Table 3 ). In sepsis, CRP levels showed a trend to lower levels in early presenters without reaching statistical significance (median, 16. 
Discussion
The main findings of our study are as follows: first, we showed that the inflammatory response at the time of CAP diagnosis was influenced by the time since onset of symptoms. Second, we showed that the CRP level was significantly lower in patients presenting less than 3 days since onset of symptoms, whereas PCT, IL-6, and IL-8 were already elevated. Third, we showed that PCT, IL-6, and IL-8 were significantly reduced after 3 days of symptoms but that CRP was still increased; these findings were confirmed for PCT and CRP in the validation cohort. The inflammatory patterns were maintained in patients with sepsis in the derivation cohort, and a similar trend was observed in the validation cohort. On the basis of these results, we believe that the initial biomarker levels at CAP diagnosis should be interpreted considering the number of days since the onset of CAP symptoms.
In this study, we have demonstrated that the inflammatory systemic response differs at the time of CAP diagnosis, specifically when many clinical decisions are made, depending on the number of days since symptoms onset. In the derivation cohort, the median time since symptom onset to CAP diagnosis was 5 days, with 22.6% of patients diagnosed within the first 48 hours, similar to prior publications (27) and very similar to the percentage in the validation cohort. Patients who had more comorbidities, had higher initial severity (PSI IV-V), and were older tended to present sooner at the ER in both cohorts. This may reflect their greater awareness of respiratory symptoms and the risk of poor evolution.
The inflammatory profile in nonearly presenters was characterized by lower expressions of PCT and proinflammatory cytokines, apart from CRP, compared with those patients with 3 days or less from onset of symptoms, probably because the more intense infection phase has ended. Our findings were corroborated in the validation cohort, even though the biomarker analysis methods were not identical. Our data could be explained by a depletion and exhaustion of biomarker production over time in the process of fighting microorganisms. To our knowledge, there are no comparable published data in patients, apart from the study by Calbo and colleagues, who performed a small study in 32 adults with pneumococcal CAP, splitting them on early (,48 h) or late-comers (25). Dallaire and colleagues, in a mouse model of pneumococcal pneumonia, determined that a plateau of bacterial growth was reached at 36 hours and that of inflammatory mediators at 84 hours after infection, followed by a posterior bacterial load drop after 92 hours (24) . Reyes and colleagues, in a baboon animal pneumonia model, described that after a challenge with S. pneumoniae there is a rapid (24 h) increase in serum proinflammatory cytokines and chemokines, which remain increased during 5 to 6 days, with a later rapid decline after antibiotic treatment (26, 28) .
The systemic inflammatory pattern in patients diagnosed within less than 3 days of symptom onset showed a greater inflammatory expression of IL-6, IL-8, and PCT, supporting the idea of a more robust early response during the first days except for CRP, which has slower kinetics (29) . A delay of 48 hours in the peak levels of CRP with regard to IL-6 (main inducer of CRP production in hepatocytes) has been documented in animal models and healthy volunteers after IL-6 stimulation (30, 31) . A similar profile was confirmed in the validation cohort with regard to CRP and PCT, despite the fact that PCT levels were slightly higher in that cohort than in the derivation cohort. In fact, nonearly presenters showed CRP levels 36.4% higher than the early presenters in the derivation cohort and 38.2% in the validation cohort. On the other hand, nonearly presenters had levels of PCT 40% and 56% lower in the derivation and validation cohorts, respectively. After microorganisms enter the lung, there is an early innate immune response provoking systemic inflammation in 24 to 48 hours. Martínez-Olondris and colleagues, in a piglet pneumonia model with methicillin-resistant S. aureus, detected at 24 hours of inoculum an increase in systemic levels of IL-6, IL-8, and TNF-a (32) . CRP behaved differently, with levels increasing until Day 3 and remaining sustained until Day 7, regardless of the use of prior antibiotics. Calbo and colleagues reported similar CRP results in early presenters (.48 h), concluding that they could be related to bacterial growth, as reported in animal models of pneumonia (24, 25) . In the present study, we observed maximum CRP levels and a turning point on Day 3.
The inflammatory pattern according to time since onset of CAP symptoms was also observed in the subset of patients with higher initial severities (PSI IV-V) in the derivation cohort. We observed the same trend in PSI IV-V patients, although without reaching statistically significant difference, in the validation cohort, probably due to a beta error. On the other hand, in sepsis, CRP levels were significantly lower in early presenters than in nonearly presenters, who had levels 40.3% higher in the derivation cohort. In contrast, PCT and IL-6 or IL-8 levels were significantly higher in early presenters. A similar trend was observed in patients with sepsis from the validation cohort, with an increase in CRP of 30.3% and a decrease in PCT of 53.8% in nonearly presenters compared with the early presenters.
The clinical impact of assessing inflammation and initial severity through biomarkers (mainly PCT and CRP) and cytokines has been investigated for the management of respiratory infections (33, 34) . Our findings point to the importance of that neglected factor to interpret biomarker levels at CAP diagnosis. We highlight the possibility of underestimating the inflammatory response and, consequently, misclassifying disease severity depending on the biomarker or cytokine used. In a randomized clinical trial, Torres and colleagues reported that corticosteroid treatment added to antibiotics in patients with CAP with high initial inflammation (CRP . 15 mg/L) reduced treatment failure (14) . Nevertheless, we can speculate that in patients diagnosed within the first 48 hours since onset of symptoms, CRP could underestimate inflammatory response, because that biomarker is still in an increasing phase. Given our observations, duration of symptoms should also be considered in the design of future clinical trials evaluating the inflammatory response.
For the daily clinical practice at CAP diagnosis, we propose a simple useful recommendation: PCT (or IL-6, IL-8) is superior when assessing disease severity in patients with symptoms for less than 3 days, whereas CRP is a better choice in patients with symptoms for 3 or more days. Noteworthy, cytokine and biomarker levels found at diagnosis reflect the highest inflammatory profile reached during the CAP episode, because after antibiotic treatment their levels will rapidly (IL-6, IL-10, PCT) or more slowly (IL-8) decline (35) .
Our study has some limitations. Notably, the time since symptom onset was self-reported (or reported by close relatives) and dependent on the subjective perception of symptoms and will have been influenced by demographic, cultural, socioeconomic, tolerance, and another external factors (36) . However, in this kind of clinical research there is no objective way to determine the exact onset of CAP infection, opposite to what occurs for other causes of sepsis (e.g., wounds) (37) . In addition, we have no data about the first symptom to appear. In the case of influenza, oseltamivir is more effective during the first days after the onset of fever. It would be interesting to analyze these data in a prospective study (38) . Another limitation is that microbiological testing was not systematically done to diagnose viruses. Indeed, it is known that the inflammatory response to viral infections, alone or combined with bacteria, has a different pattern to that shown for bacterial infections (39, 40) . Our validation cohort has no cytokine data, although we consider that, for clinical purposes, data on CRP and PCT are easily available in most hospitals.
Conclusions
In summary, these results highlight the influence of time since onset of symptoms until presentation on the interpretation of inflammatory markers in CAP. Patients who present 3 or more days after onset of symptoms may have decreased levels of some biomarkers (e.g., PCT, IL-6, and IL-8), whereas, in those diagnosed within the first 48 hours, the inflammatory response measured by CRP is still in an increasing phase, even in patients with more severe disease. Our findings have easy and rapid clinical translation at CAP diagnosis to avoid underestimation of host response: PCT (and/or IL-6, IL-8) investigation is recommended in patients with 48 hours or less since onset of symptom, whereas CRP is better in patients with 3 days or more. Thus, we conclude that the inflammatory response must be interpreted taking into account the duration of symptoms in clinical assessment at CAP diagnosis and also when designing and conducting randomized clinical trials. n Author disclosures are available with the text of this article at www.atsjournals.org. ORIGINAL ARTICLE
